also reported a low risk of hypoglycemia, with events occurring in similar proportions of patients with obesity but without diabetes who were treated with liraglutide 3.0 mg (1.3%) compared with placebo (1.0%) [37]
For milder symptoms, over-the-counter remedies like Dramamine can also provide short-term relief
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
Female sex is widely recognized as an independent factor associated with greater BW loss achievement following treatment with GLP-1 RAs, a superiority observed in the majority of studies [47, 48]
however, this can take some time